Top

Published in:

01-10-2007 | Abstracts

Poster Presentations

Authors: C. R. Knight, J. van den Wilkinson

Published in: Drug Safety | Issue 10/2007

Excerpt

Background: There are concerns from within industry and society about the appropriate safety monitoring of new medicines in the period following their launch. [1–3] …

Drazen J. Cox-2 inhibitors: a lesson in unexpected problems. N Engl J Med 2005; 352(11): 1131–2PubMedCrossRef

Griffin M. Postmarketing surveillance for drug safety: Surely we can do better. Clin Pharmacol Ther 2004; 75(6): 491–4PubMedCrossRef

Reidenberg M. Improving how we evaluate the toxicity of approved drugs. Clin Pharmacol Ther 2006; 80(1): 1–6PubMedCrossRef

Title: Poster Presentations
Authors: C. R. Knight
J. van den Wilkinson
Publication date: 01-10-2007
Publisher: Springer International Publishing
Published in: Drug Safety / Issue 10/2007
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI: https://doi.org/10.2165/00002018-200730100-00045

At a glance: The STEP trials

Springer Medicine

Poster Presentations

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 10/2007